Compare Fastly Inc (FSLY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Novo Nordisk A/S — how do they compare? Fastly Inc trades at $20.33 (market cap $3.13B), while Novo Nordisk A/S trades at $51.57 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 71× Fastly Inc's market cap, and Novo Nordisk A/S pays a 3.56% dividend while Fastly Inc pays none. Which is the better fit depends on your goals.
| FSLY | NVO | |
|---|---|---|
Market Cap | $3.13B | $222.24B |
Sector | Technology | Health |
52-Week High | $33.50 | $71.70 |
52-Week Low | $6.36 | $35.29 |
Enterprise Value | $3.20B | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $20.90, up 4.34% today, showing strong momentum after three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with positive moving averages and trades near key resistance at $21-$22. Revenue growth continues at 20% year-over-year, though the company remains unprofitable with a -15.79% net margin. Recent news highlights strategic partnerships in edge computing and AI infrastructure development.
Despite consistent revenue growth and improving margins, Fastly faces profitability challenges with negative ROE and cash flow volatility. Analyst consensus is mixed with 29% buy ratings but a $24.25 price target suggesting 16% upside. Key risks include competitive pressure from larger cloud providers and the company's ability to achieve sustainable profitability amid heavy infrastructure investments.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
